Phase 3 Study of SNF472 for Calciphylaxis

PHASE3CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

February 12, 2020

Primary Completion Date

October 24, 2022

Study Completion Date

October 24, 2022

Conditions
CalciphylaxisCalcific Uremic Arteriolopathy
Interventions
DRUG

Experimental: SNF472

Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks

DRUG

Placebo Comparator: Placebo

Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions fo 12 weeks

DRUG

Experimatenl SNF472 (Open-label)

Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks

Trial Locations (58)

10461

DaVita Clinical Research, The Bronx

18017

Fresenius Kidney Care, Bethlehem

19013

DaVita Clinical Research, Chester

22704

Fresenius Kidney Care, Durham

23320

DaVita Clinical Research, Chesapeake

23502

DaVita Clinical Research, Norfolk

24014

Fresenius Kidney Care, Roanoke

27101

Piedmont Dialysis Center, Winston-Salem

28801

DaVita Clinical Research, Asheville

29203

Fresenius Kidney Care, Columbia

33024

DaVita Clinical Research, Hollywood

33431

Boca Nephrology, PA, Boca Raton

33614

DaVita Clinical Research, Tampa

Fresenius Kidney Care, Tampa

34667

Novel Outcomes Research, Spring Hill

37923

Knoxville Kidney Center, Knoxville

39601

Fresenius Kidney Care, Brookhaven

43215

Hypertension Nephrology Consultants, Inc, Columbus

48066

DaVita Clinical Research, Roseville

48341

Michigan Kidney Consultants, Pontiac

53226

DaVita Clinical Research, Wauwatosa

55404

DaVita Clinical Research, Minneapolis

64111

DaVita Clinical Research, Kansas City

77004

DaVita Clinical Research, Houston

78212

Clinical Advancement Center, San Antonio

80230

Colorado Kidney Care, Denver

85035

AKDHC Medical Research Services, Phoenix

89128

DaVita Clinical Research, Las Vegas

89511

Fresenius Kidney Care, Reno

90260

DaVita Clinical Research, Lynwood

91204

Kidney Disease Medical Group, Glendale

91773

North America Research Institute, San Dimas

92027

California Institute of Renal Research, Escondido

92111

Fresenius Kidney Care, San Diego

92243

California Institute of Renal Research, El Centro

92505

Apex Research of Riverside, Riverside

95687

Amicis Research Center, Vacaville

02114

Massachusetts General Hospital, Boston

Unknown

Clinques Universitaries de Bruxelles Hopital, Brussels

UZ Leuven, Leuven

AZ Delta, Roeselare

Nephrologischen Zentrum Villingen-Schwenningen, Villingen-Schwenningen

Charite Universitaetsmedizin Berlin - Campus Charite Mitte, Berlin

DaVita Deutschland AG, Düsseldorf

Centrum Dializ Fresenius, Ośrodek Dializ nr 10 w Bydgoszczy 85-826, Bydgoszcz

Centrum Dializ Fresenius, Ośrodek Dializ nr 18 w Krakowie.., Krakow

Uniwersytecki Szpital Kliniczny nr 1 im. N. Barlickiego w Lodzi Stacja Dializ,, Lodz

DaVita Sp. z o.o., Stacja Dializ w Miechowie, Miechów

Centrum Dializ Fresenius Ośrodek Dializ nr 32 w Radomiu 26-617 ., Radom

Hospital Universitario Reina Sofia, Córdoba

Royal Devon and Exeter Hospital (Wonford), Exeter

Queen Elizabeth University Hospital Campus, Glasgow

Queen Elizabeth Hospital, Birmingham

08025

Fundacio Puigvert, Barcelona

08036

University of Barcelona Hospital Clinic, Barcelona

M6 8HD

Salford Royal NHS Foundation Trust, Salford

le5 4pw

Leicester General Hospital, Leicester

SE59RS

Kings College Hospital, London

All Listed Sponsors
lead

Sanifit Therapeutics S. A.

OTHER

NCT04195906 - Phase 3 Study of SNF472 for Calciphylaxis | Biotech Hunter | Biotech Hunter